{"entity":{"id":"nct07636226","kind":"trial","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","aka":[],"tldr":"A phase 2/3 trial of iparomlimab and tuvonralimab and anlotinib in lung cancer, run by Sun Yat-sen University, not yet recruiting.","summary":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer is a phase 2/3, randomised interventional study registered as NCT07636226 by Sun Yat-sen University, with a registry enrolment figure of 120 participants, started 2026-07-30 and due to reach its primary completion in 2028-12-30. Interventions recorded: QL1706; Anlotinib. Conditions listed: Small Cell Lung Cancer. Primary outcome: OS. Lung eligibility wording from the registry: \"Small cell lung cancer or lung squamous cell carcinoma confirmed by tissue or pathological examination\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07636226","url":"https://clinicaltrials.gov/study/NCT07636226"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["iparomlimab-tuvonralimab","anlotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07636226","phase":"2/3","setting":"A Multicenter, Open-label, Randomized Controlled Phase II/III Study Evaluating the Efficacy and Safety of QL1706 in Combination With Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","sponsor":"Sun Yat-sen University","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07636226/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}